News

National Cancer Institute (NCI) Awards Isoprene Pharmaceuticals, Inc. a Two-Year $2 Million Small Business Innovation Research (SBIR) Grant

isoprene

University of Maryland, Baltimore (UMB) startup is part of University’s New Ventures Initiative, a highly selective program that works to accelerate commercialization and exit strategies BALTIMORE, Sept. 7, 2021 /PRNewswire/ — Isoprene Pharmaceuticals, Inc., an early-stage small molecule oncology company developing oral therapeutics for triple negative breast cancer (TNBC) and other cancers, today announced that the National […]

Comments Off on National Cancer Institute (NCI) Awards Isoprene Pharmaceuticals, Inc. a Two-Year $2 Million Small Business Innovation Research (SBIR) Grant Continue Reading →

Empower Therapeutics Inc. Granted Exclusive License to Develop Digital Therapeutics Platform for Neuromodulation of Pain Sensitivity

Empower TX

Technology developed by scientists at the University of Maryland, Baltimore (UMB) and the University of Birmingham, U.K. BALTIMORE, Aug. 19, 2021 /PRNewswire/ — Empower Therapeutics Inc., a Baltimore-based startup, has secured worldwide, exclusive rights to a simple, reliable brainwave biomarker for pain sensitivity. Empower plans to leverage the technology, which is jointly owned by the University of Maryland, Baltimore (UMB) and […]

Comments Off on Empower Therapeutics Inc. Granted Exclusive License to Develop Digital Therapeutics Platform for Neuromodulation of Pain Sensitivity Continue Reading →

Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis

Sagimet

FOR IMMEDIATE RELEASE San Mateo, California, August 16, 2021 – Sagimet Biosciences, a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that clinicians recently dosed the first patient with nonalcoholic steatohepatitis (NASH) in its FASCINATE-2 Phase 2b clinical trial. Eduardo Bruno Martins, MD, DPhil, Sagimet’s chief […]

Comments Off on Sagimet Biosciences Doses First Patient in FASCINATE-2 Phase 2b Trial in NASH Patients with Moderate to Advanced Fibrosis Continue Reading →

MaxCyte Cell-Engineering Platform Boosts Development Programs of 14 Different Companies

Doug-Doerfler-4X6-Final-Maxcyte-Feb-2020-DSC_9203-Coyle-Studios-200x300

The next major wave of treatment options for multiple diseases is cell therapies, and Gaithersburg-based MaxCyte is one of the companies driving this revolution. So far, nine different cell therapies have been approved by the U.S. Food and Drug Administration, with CAR-T therapies being among the first to receive the green light. More cell-based therapies […]

Comments Off on MaxCyte Cell-Engineering Platform Boosts Development Programs of 14 Different Companies Continue Reading →

UMB Grants Pumas-AI Exclusive License of Analytics Platform to Enhance Drug Development

PumasAI

Company spun out of University of Maryland School of Pharmacy provides a sophisticated pharmaceutical modeling and simulation platform with upgraded Productivity and Compliance Suites BALTIMORE, Aug. 16, 2021 /PRNewswire/ — Pumas-AI, a University of Maryland, Baltimore (UMB) startup company, has been granted worldwide, exclusive rights to enhancements to Pumas, an end-to-end pharmaceutical modeling and simulation platform for quantitative analysis across the drug development […]

Comments Off on UMB Grants Pumas-AI Exclusive License of Analytics Platform to Enhance Drug Development Continue Reading →

Published Results from Sagimet’s FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640’s Ability to Significantly Reduce Excess Liver Fat

Sagimet

– Secondary analysis showed improvements of metabolic, inflammatory, and fibrotic markers San Mateo, California, July 26, 2021 – Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that Gastroenterology – the official journal of the American Gastroenterological Association – published results from the company’s FASCINATE-1 Phase 2a clinical […]

Comments Off on Published Results from Sagimet’s FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640’s Ability to Significantly Reduce Excess Liver Fat Continue Reading →

CoapTech Receives CE Mark Approval and CPT Procedure Code for Its PUMA-G System

Puma

BALTIMORE, July 14, 2021 /PRNewswire/ — CoapTech, Inc, a medical device company focused on delivering transformative solutions for minimally-invasive surgery, announced today it has received CE Mark certification, as well as an approved CPT Procedure Code for its PUMA-G System, the world’s first and only ultrasound gastrostomy system that allows physicians to place gastrostomy tubes at the point of care, […]

Comments Off on CoapTech Receives CE Mark Approval and CPT Procedure Code for Its PUMA-G System Continue Reading →

GlycoMimetics CEO Rachel King Included Among I95 BUSINESS’ Six Powerful Women Leaders in Life Sciences

Rachel 2018-09-28 Glycomimetics retouch-2-2

Editor’s Note: The Mid-Atlantic region is chocked full of high-profile health care companies that call Maryland home. Many of them are led by brilliant, innovative leaders who just happen to also be women.  Rachel K. King, Co-Founder and CEO, GlycoMimetics, Inc. Rachel K. King co-founded GlycoMimetics, Inc. (GMI) in 2003 and has served as its CEO […]

Comments Off on GlycoMimetics CEO Rachel King Included Among I95 BUSINESS’ Six Powerful Women Leaders in Life Sciences Continue Reading →

BioTalk Podcast Gets Inside Scoop on RNADD’s Exclusive License to Cutting-Edge Molecular RNA Dx Platform Technology from UMB and UMBC

block

Dr. Dipanjan Pan and Phil Robilotto of the University of Maryland, Baltimore, join BioTalk to discuss RNA Disease Diagnostics, UM Ventures, and the commercialization of new medical technologies Listen via Apple http://apple.co/3bsUsda, Google http://bit.ly/38l26Vd , Spotify http://spoti.fi/38kp9zu, and TuneIN http://bit.ly/2MVFqDp. Prof. Dipanjan Pan, MS, Ph.D., is an expert in nanomedicine, molecular imaging, drug delivery, and biosensing. He is presently a […]

Comments Off on BioTalk Podcast Gets Inside Scoop on RNADD’s Exclusive License to Cutting-Edge Molecular RNA Dx Platform Technology from UMB and UMBC Continue Reading →

GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer

2019-08-01 Glycomimetics-106_eric feldman

ROCKVILLE, Md.–(BUSINESS WIRE)–Feb. 23, 2021– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the promotion of Eric Feldman, M.D., to Senior Vice President and Chief Medical Officer. Dr. Feldman joined the Company in 2019 and was previously Vice President, Global Clinical Development. “Eric is internationally recognized for his work in the development of new therapies for the treatment of leukemias and related bone […]

Comments Off on GlycoMimetics Promotes Dr. Eric Feldman to Chief Medical Officer Continue Reading →